A medical technology company focused on developing, manufacturing and commercializing a new category of injectable aesthetic products for the dermatology and plastic surgery markets.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Anything that has to do with cosmetic surgery (as long as it is FDA approved) will succeed.
So True! As I noted to the other posters; my wife and I both have used ArteFill and 15 months later are wrinkles are smoother then when we first had ArteFill injected. When you compare to other temporary solutions, it is really amazing. When you couple this with the fact that the product also has many potential medical applications in the GERD ($14 billion market) and urinary incontinence ($10 billion). They have successfully defended their patent, so this product and stock really has only upside potential.
I have been holding this 'highly speculative' stock for many mo.s with exactly those thoughts in mind, especially the other medical uses with huge markets. But the only thing that has happened is that Schwab approached me wanting to rent my stock--obviously for the shorts who are now having a great time. Hopefully the new directors will instill new life in this stock-if not the co.